chrisvoncsefalvay/vaers-outcomes huggingface dataset:
My dad was previously on a blood thinner (plavix) for heart conditions.  This blood thinner worked well and if he would lightly scrape or nick himself  it would take ten minutes for his blood to clot.  Then, my dad  received the j and j booster and a little over a month later developed server blood clots in both legs. He underwent six surgeries on his legs (18 plus hours in operation room), a week in critical care, and  almost three weeks of hospitalization in a standard room. He left the hospital with a walker and a full-time catheter. At this very moment they have him on two blood thinners. His catheter keeps clotting and blood in his urine. I would like to add that immediately after the booster for days following  my dad had headaches, extreme tiredness, and seemed in a haze or not his typical self.
Pt c/o redness, pain, swelling and limited mobility in right deltoid the evening he was vaccinated. Guardian of pt. applied ice for treatment. All symptoms except pain resolved by 7/25/16
On December 27, 2022, I began to have a scratchy throat. I tested negative for three days. On December 31, 2022, I went to the urgent care and received antibiotic and steroid. On January 2, 2023, I tested at home and was positive for COVID-19. I had a runny nose and sneezing and fatigue that included a headache. I took PAXLOVID and I tested negative yesterday.
It was reported that a female pt received an Imovax IM, a Gamma Globulin (unspecified) and a Tetanus (unspecified) vaccination on 03-05-2000. Reportedly after the fourth dose the pt experienced very deep pain in left leg. Additional information is being requested. From correspondence received on May 15, 2000, it was reported, she was not seen in the ER on 4/3/00 or 03/05/00. She does however have a private MD. She was seen here after office hours for pain control only.
nausea, headache, rash, immediately post vaccine epi was given  patient d/c recovered
Waited little too long as about 6 months since 1st; This case was reported by a consumer via interactive digital media and described the occurrence of drug dose administration interval too long in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   Previously administered products included Shingles vaccine (The patient received 1st dose of shingles vaccine on an unknown date).   On 1st October 2022, the patient received the 2nd dose of Shingles vaccine. On 1st October 2022, unknown after receiving Shingles vaccine, the patient experienced drug dose administration interval too long. On an unknown date, the outcome of the drug dose administration interval too long was unknown.       Additional Information: GSK Receipt Date: 01-OCT-2022 Reporter's Comment: This case was reported by a patient via  interactive digital media. The patient stated that, he/she waited a little too long as about 6 months since his/her first shot of shingles vaccine. The patient stated that, hopefully he/she was good. The patient further stated that, they said he/she might have to get 2 more close together but he/she was not sure insurance would cover.  This scared the hell out of him/her more than covid. Additional Supportive Information: The patient received 2nd dose of shingles vaccine later than the recommended schedule which led to lengthening of vaccination schedule. The follow up would not possible as no contact details were available. Since the exact  interval of administration was not clear and just is stated about 6 months being conservative  drug dose administration interval too long was coded.
This case was reported by a pharmacist via call center representative and described the occurrence of dizziness in a 65-year-old female patient who received SHINGRIX for prophylaxis. On an unknown date, the patient received the 1st dose of SHINGRIX. On an unknown date, unknown after receiving SHINGRIX, the patient experienced dizziness and nausea. On an unknown date, the outcome of the dizziness and nausea were unknown. It was unknown if the reporter considered the dizziness and nausea to be related to SHINGRIX. Additional details were provided as follows: The age at vaccination was not reported. The batch number and expiration date was not reported. The pharmacist reported that the patient felt dizzy, nauseated and faint after receiving SHINGRIX.
Difficult breathing, swelling of the throat, chills, cough, headache, bodyache, fatigue.
Patient received Moderna vaccine however should have received Pfizer.  To note the patient is 17, however will be 18 in 3 days.  No adverse reaction noted.  Reported to physician and no concerns medically for patient.
Headache; Fever: She said that she started with kind of chills and shakes; Fever: She said that she started with kind of chills and shakes; she was not feeling too good; real high heart rate that were in the 110's that last for lasted for hours; Fever; This is a spontaneous report from a contactable nurse reported for herself. A 59-year-old female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, batch/lot number: EK9231 and expiration date unknown), via intramuscular on left deltoid on 03Jan2021 09:13 at single dose for COVID-19 prophylaxis. The patient medical history and concomitant medications reported as none. The reporter is a registered nurse that reported that she had the first Covid-19 vaccine yesterday morning on 03Jan2021 and she had side effects. She reported that she had a fever, headache, and a real high heart rate that was in the 110's that last for lasted for hours. She said that she started with kind of chills and shakes 11 hours and 40 minutes after receiving the vaccine. One minute she was fine and the next minute she was feeling chilled. By the time she got home from her mother's house, which is a hours drive, she was not feeling too good. Her fever broke today 04Jan2021 at around 04:00 and when she checked her temperature it was 98.7 degrees. She said that 100.2 degrees was the highest temperature she recorded. The patient said that it was a mild fever. Her headache started about 22:00 03Jan2021. The patient said that she still has the headache a little bit and she has been treating it with Tylenol and it has gotten better. She said that she wears a fit bit that tracks her heart rate and she can hear her heartbeat in her ears and she could hear it going fast. Caller said that her heart rate was down to 98 beats per minute at 06:30 this morning. She said that her current heart rate was Body temperature. Caller said that her high heart rate had her very concerned. She said that it is not normal. She is supposed to go back on 30Jan2021 to get her 2nd injection. Should she still plan on getting the second part of the vaccine? The reporter assessed event real high heart rate that were in the 110's that last for lasted for hours as serious with medically significant. Other events were assessed as non serious. The outcome of the events fever and real high heart rate that were in the 110's that last for lasted for hours was recovered on 04Jan2020, outcome of the event headache was recovering, outcome of the other events was unknown.; Sender's Comments: Based on the close temporal relationship, the association between the event high heart rate with BNT162b2 can not be completely excluded.
Developed chills, low grade fever, difficulty breathing, malaise ("no energy"), upper respiratory congestion, then sore throat, and chest congestion starting 22-23 hours after influenza vaccine.  No arm swelling or redness.  Off work for 5 days.  No treatment by primary care, urgent care or emergency care.  Took OTC Nyquil and ibuprofen.  Symptoms improved after five days off work.  No similar symptoms in family around time of her symptoms.
Information was received on 06-OCT-2017 from a lawyer regarding a case in litigation concerning a male patient of unknown age. No information was received regarding the patient's medical history, concurrent conditions or concomitant medications. It is complained and alleged that the patient was inoculated with a dose of ZOSTAVAX vaccine (dose, route and lot # were not reported) on or about 29-JUL-2014 at a pharmacy, as recommended for routine adult health maintenance and for the prevention of shingles. It was reported that the vaccine did not prevent shingles as intended, but rather caused the patient to contract a persistent strain of herpes zoster. On or about  24-SEP-2015, the patient was treated in the office by his physician for the onset of a severe vesicular rash accompanied by weakened immune symptoms, which was diagnosed as herpes zoster, or shingles. On or about 07-OCT-2015, the patient sought subsequent treatment from the same physician for ongoing and worsening outbreaks of shingles. The patient has been prescribed ZORIVAX and NORCO for management of his painful condition. As a direct and proximate result of these malfunctions, the patient suffered painful injuries and damages and required extensive medical care and treatment. As a further proximate result the patient has suffered and will continue to suffer significant medical expenses, pain and suffering and other damages. Additional information has been requested.
Nausea; vomiting; severe headache; leg pain; tingling; This case was reported by a consumer via call center representative and described the occurrence of nausea in a 51-year-old patient who received Herpes zoster (Shingrix) for prophylaxis.   On 21st November 2017, the patient received the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced nausea, vomiting, headache, leg pain and tingling. On an unknown date, the outcome of the nausea, vomiting, headache, leg pain and tingling were unknown.   It was unknown if the reporter considered the nausea, vomiting, headache, leg pain and tingling to be related to Shingrix.  Additional details were provided as follows: The age at the vaccination was not reported. The patient experienced nausea, vomiting severe headache leg pain and tingling.
Dactilitis of the big toe,  metatarso-phalangeal joint arthritis 4th toe No history of psoriatic arthritis or psoriasis
Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 72-year-old female patient (not pregnant) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 10Nov2022 at 12:45 as dose 5 (booster), single (Batch/Lot number: unknown), in left arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown), as dose 3 (booster), single (Batch/Lot number: unknown) and as dose 4 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "High blood pressure" (unspecified if ongoing); "known allergies: Penn" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "Treatment of COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Positive, notes: Treatment of COVID-19; Positive, notes: positive by thursday; Negative, notes: covid tested negative Monday. Therapeutic measures were taken as a result of drug ineffective, covid-19.  Additional information: The patient had not received any other medication in 2weeks. Rebound of covid tested negative Monday positive by Thursday  The information on the batch/lot number for BNT162b2, BNT162b2 omi ba.4-5 has been requested and will be submitted if and when received.
Hospitalization for pleura effusion/pneumonia  due to COVID-19 on dates 11/3/22- 11/9/22. Treated with vitamin C 1,000 mg PO daily, vitamin D 25 mcg PO daily, zinc 50 mg PO daily.
Vaccination error. A non-serious spontaneous report of administration of FLUMIST to a six month old was received from a physician involving a six month old female subsequent to administration of FLUMIST. Relevant medical history and concomitant medications were not reported. On 14 Sept 2009, the patient received FLUMIST. There was no adverse event associated with this medication error, therefore treatment and reporter/sponsor causality assessments are not applicable and the event is considered to be resolved. This case is submitted in accordance with MedImmune's post-marketing commitment on accelerated reporting for the newly indicated population of 2 years to 59 months of age for FLUMIST.
got 2nd dose of Shingrex and got shingles in my right eye. very painful and caused my left eye to try and unsuccessfully focus with watering and scratchimess of right eye.
First night patient experienced restlessness and cold.  Within 48hrs she developed first lesion.  Went to doctor who diagnosed shingles.
Around January 17th 2022 - Initially it felt like cold air was intermittently rushing over my right quad muscle with pants on. That lasted for about 1 week and then it developed in the other quad muscle. Again when I had long pants on.  February 19th I was exposed to extreme cold in my fingers and face. The rest of the body was covered up.  February 21 I was woken up from sleep with the feeling that my outer left leg was cold and air was rushing over it.  I was under the covers. This progressed to the other leg , both hands/fingertips  tingled, my face/lips and tongue started to tingle and still do. Bottom of my feet burn and feel hot. Slight metallic taste in my mouth occurs periodically. The burning sensation progressed to groin and chest 3/15/2022.
shingles; post-herpetic neuralgia; all of its sequelae; This spontaneous report was received from a lawyer and a 56-year-old female patient regarding a case in litigation on 10-AUG-2021. The patient's concurrent conditions, medical history, drug reactions or allergies were not reported. In March 2018, the patient was vaccinated with a dose of Zoster Vaccine Live (ZOSTAVAX) (dose, lot #, expiration date, route of administration, anatomical location and indication was not provided), she had 56-year-old when she received the vaccine. As a result of her receipt Zoster Vaccine Live (ZOSTAVAX), in March 2018, the patient suffered shingles and post-herpetic neuralgia, including any and all of its sequelae. As a result of the foregoing acts and omissions, the patient was caused to suffered serious and dangerous side effects including shingles and post-herpetic neuralgia, as well as other severe and personal injuries which were permanent and lasting in nature, physical pain and mental anguish, including diminished enjoyment of life, as well as the need for lifelong medical treatment, monitoring and or medications. As a result of the foregoing acts and omissions the patient required and will require more health care and services and did incur medical, health, she will in the future be required to obtain further medical and hospital care, attention and services. At the reporting time, the outcome of the events was considered as not recovered. The reporter considered the events to be related to Zoster Vaccine Live (ZOSTAVAX).
Lack of efficacy; Covid test turned out to be positive; initially a few rashes on which progressed; felt a little weird/; Exposed to a patient with Covid-19; brief/occasional chills; cough; sneezing; Strangely enough she had more energy than usual; Nasal congestion/She is still feeling stuffy; This spontaneous case was reported by a consumer and describes the occurrence of NASAL CONGESTION (Nasal congestion/She is still feeling stuffy), FEELING ABNORMAL (felt a little weird/), COUGH (cough), SNEEZING (sneezing) and DRUG INEFFECTIVE (Lack of efficacy) in a 67-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 016M20A and 012l20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On 13-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 10-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 03-Oct-2021, the patient experienced EXPOSURE TO SARS-COV-2 (Exposed to a patient with Covid-19). On 04-Oct-2021, the patient experienced FEELING ABNORMAL (felt a little weird/) and RASH (initially a few rashes on which progressed). On 06-Oct-2021, the patient experienced DRUG INEFFECTIVE (Lack of efficacy) and COVID-19 (Covid test turned out to be positive). In October 2021, the patient experienced NASAL CONGESTION (Nasal congestion/She is still feeling stuffy), COUGH (cough), SNEEZING (sneezing), ENERGY INCREASED (Strangely enough she had more energy than usual) and CHILLS (brief/occasional chills). The patient was treated with VALACYCLOVIR [VALACICLOVIR] at an unspecified dose and frequency. At the time of the report, NASAL CONGESTION (Nasal congestion/She is still feeling stuffy) and RASH (initially a few rashes on which progressed) had not resolved and FEELING ABNORMAL (felt a little weird/), COUGH (cough), SNEEZING (sneezing), DRUG INEFFECTIVE (Lack of efficacy), ENERGY INCREASED (Strangely enough she had more energy than usual), COVID-19 (Covid test turned out to be positive), EXPOSURE TO SARS-COV-2 (Exposed to a patient with Covid-19) and CHILLS (brief/occasional chills) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 06-Oct-2021, SARS-CoV-2 test: positive (Positive) Positive.         No concomitant medications were provided.; Sender's Comments: This case concerns a 67-year-old, female patient with no medical history reported, who experienced the unexpected non-serious adverse event of special interest of COVID-19 together with other non-serious unexpected and expected events. Drug ineffective was considered also an additional event. The event of COVID-19 occurred approximately 8 months and 24 days after the second dose of Spikevax (Moderna COVID-19 vaccine). The rechallenge was not applicable since the events occurred after the second dose. The benefit-risk relationship of Spikevax (Moderna COVID-19 vaccine) is not affected by this report.
Pt states was feeling fatigued and had body aches, as well as a rash/hives that formed on the same arm as vaccination but not at the vaccination site.
pt recv vax 27DEC95 & pt devel chickenpox w/approx 200 lesions;
No adverse event; Received Moderna Covid-19 vaccine, Bivalent injection in the back of her arm.; This spontaneous case was reported by a patient family member or friend and describes the occurrence of INCORRECT ROUTE OF PRODUCT ADMINISTRATION (Received Moderna Covid-19 vaccine, Bivalent injection in the back of her arm.) and NO ADVERSE EVENT (No adverse event) in a 71-year-old female patient who received mRNA-1273 BIVALENT (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. AS7140C) for COVID-19 prophylaxis.     It was unknown whether the patient had medications, food and other products allergies.  It was unknown if patient ever had COVID positive test or diagnosis.  It was unknown whether the patient had history relating to mentioned adverse event and both acute and chronic illnesses at the time of vaccination.     On 03-Sep-2022, the patient received dose of mRNA-1273 BIVALENT (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 03-Sep-2022, the patient experienced INCORRECT ROUTE OF PRODUCT ADMINISTRATION (Received Moderna Covid-19 vaccine, Bivalent injection in the back of her arm.). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, INCORRECT ROUTE OF PRODUCT ADMINISTRATION (Received Moderna Covid-19 vaccine, Bivalent injection in the back of her arm.) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for INCORRECT ROUTE OF PRODUCT ADMINISTRATION (Received Moderna Covid-19 vaccine, Bivalent injection in the back of her arm.).    No relevant concomitant medications were reported.   It was unknown whether patient received other vaccines within 1 month prior to Moderna COVID-19 vaccine.  It was unknown if adverse event cause patient to seek medical care.  It was unknown if the patient experienced a similar event in the past.  No treatment information was provided.
Pt reports being diaphoretic, temp 101. 24 hrs after vaccination. He states he had to be taken via ambulance to emergency care. Pt reports his physician is currently monitoring him.
(L) abdominal red maculopapular rash, very itchy and several red flat macular spots on forearm 3 weeks after ZOSTAVAX. No fevers. Is on prednisone for radiculitis.
P/receiving Typhoid vax, pt devel erythema w/heat @ inject site; Thiss was dx as cellulitis & was successfully treated w/Dicloxacillin every 6 hrs for 1 wk;
The Moderna Vaccine was given as a booster at 3:30pm on Jan 19, 2022. At 5:00 am the following day on Jan. 20t, 2022 the following reactions were experienced: chills, shivering, muscle & joint pain, high fever (104 degrees), heavy brain fog and muscle weakness resulting in paralysis (inability to get out of bed, stand, properly care for self, or even reach for a cell phone on a nearby night table). Paralysis/inability to get out of bed was experienced, and despite needing to use the restroom and wanting warmer clothes and a blanket, could not get out of bed to properly care for self. State of paralysis lasted from 5:00am to 9:00am. At 9:00am had enough mobility and dexterity back to reach for phone and get out of bed on own power. Ibuprofen and Tylenol was rotated through the day and even with the fever reducing medicine, the fever stayed between 102-103 for the entire day of Jan 20th, 2022. At about 4:00 pm on the 20th, feet felt tingly causing discomfort and unsteady balance. On January 21st, the fever came down to 101-102 with fever reducing medicine, still had muscle aches and joint pain and brain fog. Finally on January 21st, 2022 the fever was gone, and muscle soreness and joint pain felt  better but still noticeable.
headache, N/V ongoing, soreness, feeling weak   Adv pt to gently try to rehydrate with small sips of fluid or ice chips/pedialyte popsicles. If vomiting is persistent, symptoms of dehydration, or generally feeling unwell enough where home care is insufficient adv ed evaluation.
Pt. had been given for immunizations on 5/13/2013. On 5/15/2013 pt. broke out in a head to toe rash. Pt. was also given PREVNAR - Wyeth, Lot # G68911 Exp. 10/31/2014 and Hepatitis A - Merck - Lot #H010659 Exp. 03/01/2015.
THE PATIENT WAS GIVEN UNDILUTED PFIZER 5-11 YEAR OLDS COVID VACCINE 0.3ML